New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis
Go back to New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 200.56 +0.85 (0.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $199.71 | 52 Week High | $333.65 | |||
| Open | $198.88 | 52 Week Low | $223.02 | |||
| Day High | $201.22 | P/E | 25.68 | |||
| Day Low | $198.42 | EPS | $7.81 | |||
| Volume | 341,535 | |||||
